KS
Therapeutic Areas
Versatope Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VT-105 | Universal Influenza A | Phase 1 |
Leadership Team at Versatope Therapeutics
CL
Christopher Locher, PhD
Chief Executive Officer & Co-Founder
MP
M. P. Anza Mammen, MD
Chief Medical Officer
AB
Alan Barber
Chief Financial Officer
CD
Candice Del Rio, MS, RN
VP of Clinical Operations and Project Management
JL
Jessica Lee, MS, MPH
Chief Development Officer